Literature DB >> 29784842

EUCAST Determination of Olorofim (F901318) Susceptibility of Mold Species, Method Validation, and MICs.

Karin Meinike Jørgensen1, Karen M T Astvad1, Rasmus Krøger Hare1, Maiken Cavling Arendrup2,3,4.   

Abstract

Olorofim is a novel antifungal agent with in vitro activity against Aspergillus and some other molds. Here, we addressed technical aspects for EUCAST olorofim testing and generated contemporary MIC data. EUCAST E.Def 9.3.1 testing was performed comparing two plate preparation methods (serial dilution in medium [serial plates] versus predilution in DMSO [ISO plates]), two lots of olorofim, visual (visual-MIC) versus spectrophotometer (spec-MIC) reading, and four polystyrene plates using 34 to 53 Aspergillus isolates from five genera. Subsequently, olorofim MICs were compared to itraconazole, voriconazole, posaconazole, and amphotericin B MICs for 298 clinical mold isolates (2016 to 2017). Wild-type upper limits (WT-UL) were determined following EUCAST principles for epidemiologic cutoff value (ECOFF) setting. Olorofim median MICs comparing serial plates and ISO plates were identical (25/36 [69%]) or one dilution apart (11/36 [31%]). Interperson agreement for visual-MICs was 92% to 94%/100% for ≤1/≤2 dilutions, respectively. The visual-MIC values across tested microtiter plates and olorofim lots revealed only discrete differences (≤1 dilution lower for treated plates). No single spec-MIC criterion was applicable to all species. Olorofim MICs were low against 275 Aspergillus species isolates (modal MIC, 0.06 mg/liter; MIC range, < 0.004 to 0.25 mg/liter) and three dermatophytes (MICs 0.03 to 0.06 mg/liter). MICs against Fusarium were diverse, with full inhibition of F. proliferatum (MIC, 0.016), 50% growth inhibition of Fusarium solani at 1 to 2 mg/liter, and no inhibition of F. dimerum Olorofim displayed potent in vitro activity against most mold isolates and was associated with limited variation in EUCAST susceptibility testing.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  AFST; Aspergillus; EUCAST; F201318; Fusarium; amphotericin B; antifungal susceptibility; azoles; dermatophytes; olorofim

Mesh:

Substances:

Year:  2018        PMID: 29784842      PMCID: PMC6105844          DOI: 10.1128/AAC.00487-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents.

Authors:  M C Arendrup; J Meletiadis; J W Mouton; J Guinea; M Cuenca-Estrella; K Lagrou; S J Howard
Journal:  Clin Microbiol Infect       Date:  2016-02-03       Impact factor: 8.067

2.  Multicenter comparison of the ISO standard 20776-1 and the serial 2-fold dilution procedures to dilute hydrophilic and hydrophobic antifungal agents for susceptibility testing.

Authors:  Alicia Gomez-Lopez; Maiken Cavling Arendrup; Cornelia Lass-Floerl; Juan-Luis Rodriguez-Tudela; Manuel Cuenca-Estrella
Journal:  J Clin Microbiol       Date:  2010-03-10       Impact factor: 5.948

3.  High terbinafine resistance in Trichophyton interdigitale isolates in Delhi, India harbouring mutations in the squalene epoxidase gene.

Authors:  Ashutosh Singh; Aradhana Masih; Ananta Khurana; Pradeep Kumar Singh; Meenakshi Gupta; Ferry Hagen; Jacques F Meis; Anuradha Chowdhary
Journal:  Mycoses       Date:  2018-04-27       Impact factor: 4.377

4.  F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase.

Authors:  Jason D Oliver; Graham E M Sibley; Nicola Beckmann; Katharine S Dobb; Martin J Slater; Laura McEntee; Saskia du Pré; Joanne Livermore; Michael J Bromley; Nathan P Wiederhold; William W Hope; Anthony J Kennedy; Derek Law; Mike Birch
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-25       Impact factor: 11.205

5.  Mutation in the Squalene Epoxidase Gene of Trichophyton interdigitale and Trichophyton rubrum Associated with Allylamine Resistance.

Authors:  Shivaprakash M Rudramurthy; Shamanth A Shankarnarayan; Sunil Dogra; Dipika Shaw; Khurram Mushtaq; Raees A Paul; Tarun Narang; Arunaloke Chakrabarti
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

6.  In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates.

Authors:  J B Buil; A J M M Rijs; J F Meis; M Birch; D Law; W J G Melchers; P E Verweij
Journal:  J Antimicrob Chemother       Date:  2017-09-01       Impact factor: 5.790

7.  Echinocandin susceptibility testing of Candida spp. Using EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: analysis of the influence of bovine serum albumin supplementation, storage time, and drug lots.

Authors:  Maiken Cavling Arendrup; Juan-Luis Rodriguez-Tudela; Steven Park; Guillermo Garcia-Effron; Guillaume Delmas; Manuel Cuenca-Estrella; Alicia Gomez-Lopez; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2011-01-18       Impact factor: 5.191

8.  Effects of Treated versus Untreated Polystyrene on Caspofungin In Vitro Activity against Candida Species.

Authors:  Annette W Fothergill; Dora I McCarthy; Mohammad T Albataineh; Carmita Sanders; Maria McElmeel; Nathan P Wiederhold
Journal:  J Clin Microbiol       Date:  2016-01-13       Impact factor: 5.948

Review 9.  Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp.

Authors:  Maiken C Arendrup; Manuel Cuenca-Estrella; Cornelia Lass-Flörl; William W Hope
Journal:  Drug Resist Updat       Date:  2014-01-27       Impact factor: 18.500

10.  Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus.

Authors:  Clara E Negri; Adam Johnson; Laura McEntee; Helen Box; Sarah Whalley; Julie A Schwartz; V Ramos-Martín; Joanne Livermore; Ruwanthi Kolamunnage-Dona; Arnaldo L Colombo; William W Hope
Journal:  J Infect Dis       Date:  2018-03-13       Impact factor: 5.226

View more
  14 in total

Review 1.  Therapeutic Challenges of Non-Aspergillus Invasive Mold Infections in Immunosuppressed Patients.

Authors:  Frederic Lamoth; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

2.  EUCAST-Obtained Olorofim MICs against Aspergillus and Scedosporium Species and Lomentospora prolificans Showed High Agreements between Visual Inspection and Spectrophotometric Readings.

Authors:  Pilar Escribano; Ana Gómez; Elena Reigadas; Patricia Muñoz; Jesús Guinea
Journal:  Antimicrob Agents Chemother       Date:  2022-08-04       Impact factor: 5.938

3.  Olorofim Susceptibility Testing of 1,423 Danish Mold Isolates Obtained in 2018-2019 Confirms Uniform and Broad-Spectrum Activity.

Authors:  Karen Marie Thyssen Astvad; Karin Meinike Jørgensen; Rasmus Krøger Hare; Raluca Datcu; Maiken Cavling Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

Review 4.  Invasive Aspergillosis by Aspergillus flavus: Epidemiology, Diagnosis, Antifungal Resistance, and Management.

Authors:  Shivaprakash M Rudramurthy; Raees A Paul; Arunaloke Chakrabarti; Johan W Mouton; Jacques F Meis
Journal:  J Fungi (Basel)       Date:  2019-07-01

5.  In vitro activity of the novel antifungal olorofim against dermatophytes and opportunistic moulds including Penicillium and Talaromyces species.

Authors:  Ashutosh Singh; Prerna Singh; Jacques F Meis; Anuradha Chowdhary
Journal:  J Antimicrob Chemother       Date:  2021-04-13       Impact factor: 5.790

6.  Potency of olorofim (F901318) compared to contemporary antifungal agents against clinical Aspergillus fumigatus isolates, and review of azole resistance phenotype and genotype epidemiology in China.

Authors:  Huilin Su; Min Zhu; Clement Kin-Ming Tsui; Henrich van der Lee; Marlou Tehupeiory-Kooreman; Jan Zoll; Tobias Engel; Li Li; Junhao Zhu; Zihan Lu; Qiangqiang Zhang; Paul E Verweij; Shuwen Deng
Journal:  Antimicrob Agents Chemother       Date:  2021-03-08       Impact factor: 5.191

7.  In Vitro Activity of Novel Antifungal Olorofim against Filamentous Fungi and Comparison to Eight Other Antifungal Agents.

Authors:  Ourania Georgacopoulos; Natalie S Nunnally; Eric M Ransom; Derek Law; Mike Birch; Shawn R Lockhart; Elizabeth L Berkow
Journal:  J Fungi (Basel)       Date:  2021-05-12

8.  Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim.

Authors:  Wilson Lim; Kimberly Eadie; Mickey Konings; Bart Rijnders; Ahmed H Fahal; Jason D Oliver; Mike Birch; Annelies Verbon; Wendy van de Sande
Journal:  J Antimicrob Chemother       Date:  2020-04-01       Impact factor: 5.790

Review 9.  Hope on the Horizon: Novel Fungal Treatments in Development.

Authors:  Adriana M Rauseo; Ariella Coler-Reilly; Lindsey Larson; Andrej Spec
Journal:  Open Forum Infect Dis       Date:  2020-01-12       Impact factor: 3.835

Review 10.  Advances in anti-fungal therapies.

Authors:  Grant Waterer
Journal:  Mycopathologia       Date:  2021-07-15       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.